e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Regulation of airway hyperresponsiveness and bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The
in-vitro
pharmacology of PF-4522971 – A novel inhaled Muscarinic M
3
Antagonist
S. Patel, S. Marshall, S. Summerhilll, M. Strawbridge, M. Stanley, E. Stuart, M. Trevethick, M. Yeadon, N. Clarke (Sandwich, United Kingdom)
Source:
Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Session:
Regulation of airway hyperresponsiveness and bronchodilators
Session type:
Thematic Poster Session
Number:
1237
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Patel, S. Marshall, S. Summerhilll, M. Strawbridge, M. Stanley, E. Stuart, M. Trevethick, M. Yeadon, N. Clarke (Sandwich, United Kingdom). The
in-vitro
pharmacology of PF-4522971 – A novel inhaled Muscarinic M
3
Antagonist. Eur Respir J 2010; 36: Suppl. 54, 1237
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
The
in-vitro
pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β
2
adrenoceptor agonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
The
in vitro
biology of PF-00610355 – a novel β
2
adrenoceptor agonist with a long duration of action
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Demonstration of dual pharmacology
in vivo
of PF-3429281: A novel inhaled dual antimuscarinic/β
2
agonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
PF-3429281 – A novel inhaled dual antimuscarinic/β
2
adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010
Treatment of sarcoidosis – pentoxifylline
Source: Annual Congress 2009 - Pleural and parenchymal diseases
Year: 2009
Airway resistances: R
aw
, sR
aw
, sR
eff
– Which is the best determinant of airway function?
Source: Annual Congress 2010 - Lung function from infancy to adulthood
Year: 2010
Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
PF-00610355 – an inhaled β
2
adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011
Differential involvement of IκB kinases α and β in asthma and COPD
Source: Annual Congress 2010 - COPD and asthma: models and human studies
Year: 2010
Adrenomedullin – a protective factor in asthma?
Source: Annual Congress 2009 - Animal models of airways inflammation
Year: 2009
Tumor nekrozis faktor-alfa blockers and tuberculosis – Analysis of the 6 years
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Oral glucocorticoid treatment of severe asthma – Current practice in the US
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Sensitivity and specificity of airway hyperreactivity (AHR) based on methacholine challenge (MCH) tests – Comparison of sG
eff
with FEV
1
and MEF
50
as target parameter
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012
Over-reading spirometry – Man or machine?
Source: Annual Congress 2011 - Quality control in lung function and exercise-related issues
Year: 2011
Asthma medication and antibiotics – Cause or effect?
Source: Annual Congress 2010 - Paediatric respiratory epidemiology: early origins of childhood asthma
Year: 2010
EGFR – a useful biomarker?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
LungPoint® – A new approach to peripheral lung lesions
Source: Annual Congress 2010 - Tissue is mostly the issue: diagnostic and therapeutic bronchoscopy
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept